Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Facon

Showing results (81-90 of 301) with videos related to

Pageof 31
Sort By:
Leukemia & Lymphoma|January 14, 2016
Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myelomaPhilippe Moreau, Thierry Facon, Cyrille Touzeau, et al.
Cancer Medicine|October 13, 2020
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patientsAndrew Belch, Nizar Bahlis, Darrell White, et al.
British Journal of Haematology|September 4, 2009
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myelomaDan T Vogl, Edward A Stadtmauer, Paul G Richardson, et al.
Advances in Therapy|June 28, 2022
Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myelomaSagar Lonial, Ravi Vij, Jean-Luc Harousseau, et al.
Advances in Therapy|March 5, 2022
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
Blood Advances|April 21, 2021
Can palliative care consultation increase integration of palliative care for patients with hematologic malignancies?Chloé Prod'homme, Licia Touzet, Magali Pierrat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significanceXavier Leleu, Gaëlle Le Friec, Thierry Facon, et al.
Leukemia & Lymphoma|July 2, 2013
Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort studyAnnie Fourrier-Réglat, Pernelle Noize, Thierry Facon, et al.
European Journal of Haematology|August 19, 2007
Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage IThomas Gastinne, Xavier Leleu, Alain Duhamel, et al.
Pageof 31

Showing results (81-90 of 301) with videos related to

Sort By:
Pageof 31
Leukemia & Lymphoma|January 14, 2016
Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myelomaPhilippe Moreau, Thierry Facon, Cyrille Touzeau, et al.
Cancer Medicine|October 13, 2020
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patientsAndrew Belch, Nizar Bahlis, Darrell White, et al.
British Journal of Haematology|September 4, 2009
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myelomaDan T Vogl, Edward A Stadtmauer, Paul G Richardson, et al.
Advances in Therapy|June 28, 2022
Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myelomaSagar Lonial, Ravi Vij, Jean-Luc Harousseau, et al.
Advances in Therapy|March 5, 2022
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
Blood Advances|April 21, 2021
Can palliative care consultation increase integration of palliative care for patients with hematologic malignancies?Chloé Prod'homme, Licia Touzet, Magali Pierrat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significanceXavier Leleu, Gaëlle Le Friec, Thierry Facon, et al.
Leukemia & Lymphoma|July 2, 2013
Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort studyAnnie Fourrier-Réglat, Pernelle Noize, Thierry Facon, et al.
European Journal of Haematology|August 19, 2007
Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage IThomas Gastinne, Xavier Leleu, Alain Duhamel, et al.
Pageof 31